RT Journal Article
SR Electronic
T1 Privacy-Protecting, Reliable Response Data Discovery Using COVID-19 Patient Observations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.21.20196220
DO 10.1101/2020.09.21.20196220
A1 Kim, Jihoon
A1 Neumann, Larissa
A1 Paul, Paulina
A1 Aratow, Michael
A1 Bell, Douglas S.
A1 Doctor, Jason N.
A1 Hinske, Ludwig C.
A1 Jiang, Xiaoqian
A1 Kim, Katherine K.
A1 Matheny, Michael E.
A1 Meeker, Daniella
A1 Pletcher, Mark J.
A1 Schilling, Lisa M.
A1 SooHoo, Spencer
A1 Xu, Hua
A1 Zheng, Kai
A1 Ohno-Machado, Lucila
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/09/23/2020.09.21.20196220.abstract
AB There is an urgent need to answer questions related to COVID-19’s clinical course and associations with underlying conditions and health outcomes. Multi-center data are necessary to generate reliable answers, but centralizing data in a single repository is not always possible. Using a privacy-protecting strategy, we launched a public Questions & Answers web portal (https://covid19questions.org) with analyses of comorbidities, medications and laboratory tests using data from 202 hospitals (59,074 COVID-19 patients) in the USA and Germany. We find, for example, that 8.6% of hospitalizations in which the patient was not admitted to the ICU resulted in the patient returning to the hospital within seven days from discharge and that, when adjusted for age, mortality for hospitalized patients was not significantly different by gender or ethnicity.One Sentence Summary Publicly Sharing Knowledge on COVID19 Without Sharing Patient-Level Data: A Privacy-Protecting Multivariate Analysis ApproachCompeting Interest StatementHua Xu has financial interest at Melax Technologies Inc. Other authors declare no competing interests.Funding StatementFunded by the Betty and Gordon Moore Foundation #9639. The distributed analytics algorithm was funded by NIH-R01GM118609. Trainees were funded by NIH-T15LM011271. LN was funded by DIFUTURE (BMBF grant 01ZZ1804C); Author contributions: JK, LN and LO-M drafted the manuscript. PP, MA, DB, JD, LH, KK, DM, MM, MP, LS, SS, HX, KZ organized local teams for answering questions. All authors reviewed the manuscript. LO-M supervised the study and acquired the funding. See supplemental materials for a complete list of consortium authors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was approved by the University of California San Diego Human Research Protection Program, our Institutional Review Board equivalent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnswers are available at https://covid19questions.org and code is in https://github.com/DBMI/R2D2-Public.